A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma. Issue 3 (31st January 2022)

• Record Type: Journal Article
• Authors: Damato, Anna R; Katumba, Ruth G N; Luo, Jingqin; Atluri, Himachandana; Talcott, Grayson R; Govindan, Ashwin; Slat, Emily A; Weilbaecher, Katherine N; Tao, Yu; Huang, Jiayi; Butt, Omar H; Ansstas, George; Johanns, Tanner M; Chheda, Milan G; Herzog, Erik D; Rubin, Joshua B; Campian, Jian L
• Is Part Of: Neuro-oncology practice. Volume 9:Issue 3(2022)
• Page Start: 193
• Page End: 200
• Publication Date: 2022-01-31
• Subjects: chronotherapy -- feasibility -- gliomas -- quality of life; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481005
• DOI: 10.1093/nop/npac003
• Languages: English
• ISSNs: 2054-2577

Abstract

Abstract: Background: Gliomas are the most common primary brain tumor in adults. Current treatments involve surgery, radiation, and temozolomide (TMZ) chemotherapy; however, prognosis remains poor and new approaches are required. Circadian medicine aims to maximize treatment efficacy and/or minimize toxicity by timed delivery of medications in accordance with the daily rhythms of the patient. We published a retrospective study showing greater anti-tumor efficacy for the morning, relative to the evening, administration of TMZ in patients with glioblastoma. We conducted this prospective randomized trial to determine the feasibility, and potential clinical impact, of TMZ chronotherapy in patients with gliomas (NCT02781792). Methods: Adult patients with gliomas (WHO grade II-IV) were enrolled prior to initiation of monthly TMZ therapy and were randomized to receive TMZ either in the morning (AM) before 10 am or in the evening (PM) after 8 pm. Pill diaries were recorded to measure compliance and FACT-Br quality of life (QoL) surveys were completed throughout treatment. Study compliance, adverse events (AE), and overall survival were compared between the two arms. Results: A total of 35 evaluable patients, including 21 with GBM, were analyzed (18 AM patients and 17 PM patients). Compliance data demonstrated the feasibility of timed TMZ dosing. There were no significant differences in AEs, QoL, or survival between the arms. Conclusions: Chronotherapy with TMZ is feasible. A larger study is needed to validate the effect of chronotherapy on clinical efficacy.